New Insights into the Long-QT syndrome;Nuevas perspectivas en el síndrome de QT largo

Revista Espanola de Cardiologia

Volumn 60, Issue 7, 2007, Pages 675-682

  Rossenbacker, Tom ^a   Priori, Silvia G ^a,b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENE MUTATION; GENETIC DISORDER; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME; SUDDEN INFANT DEATH SYNDROME; GENETICS; GENOTYPE; MUTATION; PHENOTYPE;

GENOTYPE; HUMANS; LONG QT SYNDROME; MUTATION; PHENOTYPE;

EID: 34548029358     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13108271     Document Type: Editorial

References (57)

1. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare dell'eta' pediatrica. Clinical Pediatrics. 1963;45:656-83.
2. Ward O. A new familial cardiac syndrome in children. J Iri Med Assoc. 1964;54:103-6.
3. Imboden M, Swan H, Denjoy I, Van Langen IM. Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med. 2006;355:2744-51.
4. Jervell A, Lange-Nielsen F. Congenital deaf mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J. 1957;54:59-68.
5. Priori SG, Schwartz PJ, Napolitano C, Bianchi L, Dennis A, De Fusco M, et al. A recessive variant of the Romano-Ward long-QT syndrome? Circulation. 1998;97:2420-5.
6. Larsen LA, Fosdal I, Andersen PS, Kanters JK, Vuust J, Wettrell G, et al. Recessive Romano-Ward syndrome associated with compound heterozygosity for two mutations in the KVLQT1 gene. Eur J Hum Genet. 1999;7:724-8.
7. Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest. 2003;112:810-5.
8. Splawski I, Timothy KW, Vincent GM, Atkinson DL, Keating MD. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med. 1997;336:1562-7.
9. Neyroud N, Tesson F, Denjoy I, Atkinson DL, Keating MT. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15:186-9.
10. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet. 1997;17:267-8.
11. Wang Z, Li H, Moss AJ, Robinson J, Zareba W, Knilans T, et al. Compound heterozygous mutations in KvLQT1 cause Jervell and Lange-Nielsen syndrome. Mol Genet Metab. 2002;75:308-16.
12. Mohler PJ, Splawski I, Napolitano C, Bottelli G, Sharpe L, Timothy K, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA. 2004;101:9137-42.
13. Mohler PJ, Le Scouarnec S, Denjoy I, Guicheney P, Caron L, Driskell IM, et al. Defining the cellular phenotype of «ankyrin-B syndrome» variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation. 2007;115:432-41.
14. Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105:511-9.
15. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002;110:381-8.
16. Reichenbach H, Meister EM, Theile H. The heart-hand syndrome. A new variant of disorders of heart conduction and syndactylia including osseous changes in hands and feet. Kinderarztl Prax. 1992;60:54-6.
17. Marks ML, Whisler SL, Clericuzio C, Keating M. A new form of long QT syndrome associated with syndactyly. J Am Coll Cardiol. 1995;25:59-64.
18. Splawski I, Timothy KW, Sharpe LM, Keating MT. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31.
19. Splawski I, Timothy KW, Decher N. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA. 2005;102:8089-96.
20. Vatta M, Ackerman MJ, Ye B, Makielski JC. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114:2104-12.
21. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al. Genetic testing in the long QT syndrome. JAMA. 2005;294:2975-80.
22. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507-17.
23. Murray A, Donger C, Fenske C, Spillman I, Richard P, Dong YB, et al. Splicing mutations in KCNQ1: a mutation hot spot at codon 344 that produces in frame transcripts. Circulation. 1999;100:1077-84.
24. Napolitano C, Priori S, Schwartz PJ. Identification of a mutational hot spot in HERG-related long QT syndrome (LQT2): phenotypic implications. Circulation. 1997;96 Suppl I:212.
25. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1120-1.
26. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004;109:1834-41.
27. Arnestad M, Crotti L, Rognum TO, Schwartz PJ, Crotti L. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007;115:361-7.
28. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, Makielski JC, et al. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm. 2007;4:161-6.
29. Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res. 2005;67:388-96.
30. Berul CI, Perry JC. Contribution of long-QT syndrome genes to sudden infant death syndrome: is it time to consider newborn electrocardiographic screening? Circulation. 2007;115:294-6.
31. Tester DJ, Ackerman MJ. Posmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol. 2007;49:240-6.
32. Crotti L, Lundquist AL, Insolia R, Pedrazzini N, Ferrandi C, De Ferrari GM, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005;112:1251-8.
33. Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res. 2005;96:693-701.
34. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet. 2006;38:644-51.
35. Koopmann TT, Alders M, Jongbloed RJ, Kamakura S, Roden DM, Wilde AA, et al. Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies. Heart Rhythm. 2006;3:52-5.
36. Padgett RA, Grabowski PJ, Konarska MM, Seiler S, Sharp PA. Splicing of messenger RNA precursors. Annu Rev Biochem. 1986;55:1119-50.
37. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-7.
38. Rossenbacker T, Schollen E, Kuiperi C, De Ravel TJ, Derriend TK, Matthijs G, et al. Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy. J Med Genet. 2005;42:e29.
39. Zhang L, Vincent GM, Baralle M, De Ravel TJ, Devriendt K. An intronic mutation causes long QT syndrome. J Am Coll Cardiol. 2004;44:1283-91.
40. Crotti L, Marzena A, Lewandowska B, Cobelli F, Tavazzi L, Rampulla C. Intronic branch point mutations may contribute to the current failure of identifying mutations in patients affected by the Long QT Syndrome [abstract]. Heart Rhythm Society Abstract book. 2007.
41. Bai R, Bloise R, Ronchetti E, et al. Cost efficacy considerations for LQTS genetic screening in different groups of patients: considerations to prioritize access to molecular diagnosis [abstract]. Heart Rhythm Society Abstract book, 2007.
42. Phillips KA, Ackerman MJ, Sakowski J, et al. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm. 2005;2:1294-300.
43. Tan HL, Bardai A, Shimizu W, Berul CI. Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications. Circulation. 2006;114:2096-103.
44. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Folli R, Cappelletti D, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-74.
45. Hobbs JB, Peterson DR, Moss AJ, McNitt S, Zareba W, Goldenberg I, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006;296:1249-54.
46. Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson R, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329-37.
47. Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-gogo-related gene potassium channel. Circulation. 2002;105:794-9.
48. Rossenbacker T, Mubagwa K, Jongbloed RJ, Vereecke J, Devriendt K. Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. Circulation. 2005;111:961-8.
49. Shimizu W, Horie M, Ohno S, Takenaka K, Yamaguchi M, Shimizu M, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol. 2004;44:117-25.
50. Goldenberg I, Moss AJ, Zareba W, et al. Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol. 2006;17:1161-8.
51. Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006;113:783-90.
52. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092-8.
53. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer G, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-484.
54. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101: 616-23.
55. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95.
56. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-4.
57. Viitasalo M, Oikarinen L, Swan H, et al. Effects of beta-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome. J Am Coll Cardiol. 2006;48:747-53.